Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OGN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Mometasone FDA approved Apr 1987 · Elocon (discontinued) |
Rhinitis, Allergic, Seasonal | Phase 4 · NCT00070707 | Completed |
| Tapinarof FDA approved May 2022 · Vtama |
Plaque Psoriasis | Phase 3 · NCT03983980 | Completed |
| Montelukast FDA approved Feb 1998 · Singulair |
Allergic Rhinitis | Phase 3 · NCT01673620 | Completed |
| Etonogestrel FDA approved Jul 2006 · Implanon |
Benign Prostatic Hyperplasia (BPH) | Phase 2 · NCT00651807 | Terminated |
| Ganirelix FDA approved Jul 1999 · Ganirelix Acetate |
Pregnancy | N/A · NCT00703014 | Completed |
| Gonapeptyl® | Ovarian Stimulation | Phase 4 · NCT06175832 | Recruiting |
| VTAMA (tapinarof) cream, 1% | Psoriasis | Phase 4 · NCT05680740 | Completed |
| Puregon® | Ovarian Stimulation | Phase 4 · NCT06175832 | Recruiting |
| Orgalutran® | Ovarian Stimulation | Phase 4 · NCT06175832 | Recruiting |
| Norethindrone | Breakthrough Bleeding | Phase 4 · NCT04047875 | Completed |
| Etoricoxib | Acute Gout | Phase 4 · NCT00142558 | Completed |
| Elonva® | Ovarian Stimulation | Phase 4 · NCT06175832 | Recruiting |
| Comparator: indomethacin 75 mg sustained… | Acute Gout | Phase 4 · NCT00142558 | Completed |
| Desogestrel | Ovarian Stimulation | Phase 4 · NCT06175832 | Recruiting |
| Atozet 10/40 mg or 10/80 mg | Atherosclerotic Cardiovascular Disease | Phase 4 · NCT05761444 | Completed |
| Albuterol | Rhinitis, Allergic, Seasonal | Phase 4 · NCT00070707 | Completed |
Also used in these trials (approved or third-party drugs, not OGN's own candidates): Atorvastatin Calcium, Ezetimibe, Montelukast Sodium, Pembrolizumab, Trastuzumab, Leucovorin, Triptorelin, Progesterone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OGN holds $1.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OGN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Pentwater Capital Management LP | Institution (13G, 5%+) | 18,100,000 | 6.89% | 2026-06-30 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 15,161,710 | 5.77% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 13,717,181 | 5.22% | 2026-03-31 |
| Matthew M Walsh Chief Financial Officer · +43,094 options |
Insider | 212,746 | 0.08% | 2026-03-31 |
| Joseph T. Jr. Morrissey CEO · +87,489 options |
Insider | 153,316 | 0.06% | 2026-11-13 |
| Rachel A Stahler Chief Information Officer · +24,625 options |
Insider | 116,105 | 0.04% | 2026-03-31 |
| Aaron Falcione Chief Human Resources Officer · +22,386 options |
Insider | 101,431 | 0.04% | 2026-03-31 |
| Kirke Weaver Gen. Counsel & Corp. Secy. · +24,625 options |
Insider | 92,639 | 0.04% | 2026-03-31 |
| Vittorio Nisita Head of Global Business Svcs · +16,790 options |
Insider | 70,619 | 0.03% | 2026-03-31 |
| Daniel Karp Executive VP, Corp. Dev. · +13,432 options |
Insider | 69,548 | 0.03% | 2026-03-31 |
| Ferreira Juan Camilo Arjona Head of R&D & CMO |
Insider | 41,565 | 0.02% | 2026-11-07 |
| Juliana Papa Drinane Head of Mfg & Supply · +51,723 options |
Insider | 35,239 | 0.01% | 2026-11-13 |
Share count 262,621,584 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OGN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →